SEC Comment Letter for Stealth BioTherapeutics Corp (CIK 0001696396) — Jun 13, 2022
Stealth BioTherapeutics Corp (CIK 0001696396)
Date: June 13, 2022 · CIK: 0001696396 · Accession: 0000000000-22-006421
AI Filing Summary & Sentiment
File numbers found in text: 333-265423
Letter
United States securities and exchange commission logo June 13, 2022 Irene McCarthy Chief Executive Officer and Director Stealth BioTherapeutics Corp c/o Intertrust Corporate Services (Cayman) Limited One Nexus Way, Camana Bay Grand Cayman KY1-9005 Cayman Islands Re:Stealth BioTherapeutics Corp Registration Statement on Form F-1 Filed June 3, 2022 File No. 333-265423 Dear Irene McCarthy: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Michael Davis at 202-551-4385 or Laura Crotty at 202-551-7614 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Rosemary G. Reilly
Show Raw Text
United States securities and exchange commission logo
June 13, 2022
Irene McCarthy
Chief Executive Officer and Director
Stealth BioTherapeutics Corp
c/o Intertrust Corporate Services (Cayman) Limited
One Nexus Way, Camana Bay
Grand Cayman
KY1-9005 Cayman Islands
Re:Stealth BioTherapeutics Corp
Registration Statement on Form F-1
Filed June 3, 2022
File No. 333-265423
Dear Irene McCarthy:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Michael Davis at 202-551-4385 or Laura Crotty at 202-551-7614 with any
questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Rosemary G. Reilly